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•	 small-Cell Lung Cancers 
in Patients Who never 
smoked Cigarettes
OPTOMETRY AND VISION SCIENCE
Copyright © 2014 American Academy of Optometry
patients were never smokers. Of these, de novo SCLCs 
accounted for 83% whereas transformation to SCLC 
was found in 17% in acquired resistance to erlotinib. 
The median was 23 months from SCLC diagnosis. In de 
novo SCLC cases, the status of ALK rearrangement (0 
of 5), KRAS mutations (0 of 8), EGFR mutations (2 of 
8), and RB loss (6 of 7) were identified. Next generation 
sequencing of two de novo SCLC cases demonstrated 
potentially actionable oncogenic drivers—p53 and RB1 
mutations with amplification in TERT and CBL and GNAS 
mutations with amplification in MYCL1. (p. 892)
•	 supplementary Prognostic 
Variables for Pleural 
Mesothelioma: A Report 
from the IAsLC staging 
Committee
(pathologic staging and other CORE variables); (2) 
only clinical staging and Core variables available; 
and (3) only age, sex, histology, and laboratory 
parameters. This study determined three prognostic 
models. Scenario A (all parameters): best pathologic 
stage, histology, sex, age, type of surgery, adjuvant 
treatment, WBC (≥ 15.5 or not), and platelets (≥ 400 
k or not; n = 550). Scenario B (no surgical staging): 
clinical stage, histology, sex, age, type of surgery, 
adjuvant treatment, WBC, hemoglobin (<14.6 or not), 
and platelets (n = 627). Scenario C (limited data): 
histology, sex, age, WBC, hemoglobin, and platelets 
(n = 906). The revision of the prognostic models would 
allow stratification of patients for optimal outcome 
after surgery and guide decision to receive adjuvant 
therapy. (p. 856)
In ThIs Issue
This brief report describes clinical, pathologic, and molecular 
characteristics of never smokers with small-cell lung cancers (SCLCs). 
Smoking history, demographic, treatment, and survival data of 1040 
SCLC patients (2005–2012) were included in the study. Available 
samples were analyzed by different molecular tests for EGFR, KRAS, 
PIK3CA, ALK, and RB protein expression. Two percent of SCLC 
The International Association for the Study of Lung Cancer 
(IASLC) Staging Committee sought to revise the staging 
system for malignant pleural mesothelioma (MPM) and have 
reported supplementary prognostic variables to previously 
published CORE variables, including stage, histology, sex, age, 
and type of procedure. Three categories of data were analyzed 
for supplementary prognostic variables: (1) all data available 
•	 Triple Inhibition of 
eGFR, Met, and VeGF 
suppresses Regrowth of 
hGF-Triggered, erlotinib-
Resistant Lung Cancer 
harboring an EGFR 
Mutation
This study evaluated the effect of triple inhibition of 
EGFR, Met, and VEGF on HGF-mediated resistance 
to EGFR TKI in EGFR-mutant lung cancer, based on 
the authors’ previous findings of HGF-mediated Met 
activation in association with EGFR TKI resistance and 
angiogenesis. EGFR-mutant lung cancer cell lines, PC-9, 
HCC827, and HGF-gene transfected PC-9 (PC-9/HGF) 
cells were used to assess 3 clinically approved inhibitors/
antibody, erlotinib (EGFR), crizotinib (ALK and Met), 
and bevacizumab (VEGF), and a novel TAS-115 (Met and 
VEGF-2). In vitro findings demonstrated crizotinib and 
TAS-115 blocked Met activation and VEGF production, 
and reversed resistance to erlotinib triggered by HGF. In 
vivo findings showed that HGF-mediated angiogenesis was 
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•	 stereotactic Body 
Radiotherapy in 
Patients with Previous 
Pneumonectomy: safety 
and efficacy
years), were identified. Fourteen tumors were treated 
with SBRT in these patients, who were followed up for 
a median of 24 months. Grade 3 radiation pneumonitis 
was observed 3 and 4 months post SBRT (n = 2), 
followed by deaths (myocardial infarction in one, 
progressive dyspnea in another). There were no local 
recurrences, one regional recurrence and three cases 
of distant metastatic disease. A median survival of 29 
months was achieved; 1-year overall survival (OS) was 
69% whereas 2-year OS was 61%. The results indicate 
that SBRT in patients with prior pneumonectomy could 
provide local control and long-term survival, but careful 
planning is necessary in minimizing the risk of radiation 
pneumonitis. (p. 843)
suppressed by bevacizumab and TAS-115. Furthermore, 
the triplet erlotinib, crizotinib, and bevacizumab, or the 
doublet erlotinib and TAS-115 resulted in PC-9/HGF 
tumor growth inhibition and delayed tumor regrowth 
correlated with continuous block in angiogenesis post-
treatment. Taken together, this study suggests that triple 
inhibition of EGFR, HGF/Met, and VEGF/VEGFR-2 
(through clinical drug triplet or TAS-115/erlotinib 
combination) could reverse resistance to EGFR TKI and 
inhibit angiogenesis, therefore suppressing progression 
of EGFR-mutant lung cancer. (p. 775)
Thompson et al. investigated the safety and efficacy of stereotactic 
body radiotherapy (SBRT) in patients with prior pneumonectomy. 
Common Terminology Criteria for Adverse Events version 3.0 
was used to report treatment toxicity. Three categories of disease 
recurrences were defined: local, regional, or distant metastasis. 
Kaplan-Meier analysis was used to determine overall survival. 
Thirteen patients with prior pneumonectomy (median age, 69 
•	 Meta-Analysis of First-Line 
Therapies in Advanced 
non-small-Cell Lung 
Cancer harboring EGFR 
Activating Mutations
This is the first meta-analysis, which included eight 
randomized phase 3 clinical trials in the last 5 years, 
comparing tyrosine kinase inhibitors (TKIs), gefitinib, 
erlotinib, and afatinib to chemotherapy as first-line 
therapy in patients with advanced non–small-cell lung 
cancer (NSCLC) harboring EGFR activating mutations. 
Predictive intervals (PI) were indicative of study-to-
study heterogeneity. The findings demonstrated that 
gefitinib, erlotinib, and afatinib were more superior 
than chemotherapy in progression-free survival (PFS), 
overall response rate (ORR), and disease control rate 
(DCR): hazard ratio meta-estimates for PFS were 0.44, 
PI 0.22–0.88 (gefitinib); 0.25, PI 0.11–0.55 (erlotinib); 
and 0.44, PI 0.20–0.98 (afatinib). Similar results were 
observed for ORR and DCR. No evidence of improved 
overall survival from gefitinib, erlotinib, or afatinib 
versus chemotherapy was found. Also, no significant 
difference between each TKI treatment was observed. 
This meta-analysis provided evidence to guide first-line 
treatment decisions for patients with advanced NSCLC 
bearing EGFR activating mutations. (p. 805)
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•	 Primary Tumor  
standardized uptake Value 
(suVmax) Measured on  
F18-Fluorodeoxyglucose 
Positron emission 
Tomography (FDG-PeT) 
is of Prediction Value for 
survival and local control 
in non-small Cell Lung 
Cancer (nsCLC) receiving 
radiotherapy:  
Meta-Analysis (MA)
(OS) and local control (LC) data were analyzed from 
these studies with sample sizes ranging from 46 to 132. 
The results demonstrated that higher pre-RT SUV
max
 
was associated with shorter OS (combined HR = 1.05; 
P
heterogeneity
 = 0.245), and poor LC (combined HR = 1.24; 
P
heterogeneity
 = 0.0255). Similar results were observed 
for post-RT SUV
max
: OS (combined HR = 1.32; 
P
heterogeneity
 = 0.670) and LC (combined HR = 2.19 and 
2.32). When stratified by stereotactic body radiotherapy 
(SBRT) and conventional radiotherapy (CRT), high pre-
SBRT SUV
max
 was significantly associated with poor 
OS (HR = 1.10; P
heterogeneity
 = 0.245), and unfavorable 
LC (HR = 1.11; P
heterogeneity
 = 0.242). Post-SBRT SUV
max
 
was associated with LC (HR = 2.19; P
heterogeneity
 = 0.204), 
but OS was not determined because of limited data. In 
CRT groups, both high pre-CRT and post-CRT SUV
max
 
were correlated to poor OS. Taken together, this study 
demonstrated a significant correlation of high level of 
pre-RT or post-RT SUV
max
 with higher risk of death and 
local recurrence, regardless of treatment types (SBRT 
or conventional radiation). This relationship seemed 
particularly strong in patients with Stage I NSCLC 
treated with SBRT. (p. 834)
ReseARCh WATCh
•	 Ceritinib in ALK-
Rearranged non–small-
Cell Lung Cancer
≥ 400 mg/d of ceritinib showed a response rate of 56% 
(prior crizotinib) and 62% (without prior crizotinib). 
Responses were also observed in patients whose 
disease had progressed on prior crizotinib treatment 
irrespective of the presence of resistance mutations 
in ALK. The most common toxicities were nausea, 
diarrhea, vomiting, fatigue, elevated aminotransferase 
levels. No treatment-related deaths. The authors 
concluded that ceritinib was highly active in advanced 
NSCLC with ALK rearrangement, including those with 
disease progression on crizotinib, despite the presence 
of ALK resistance mutations.
Shaw AT, Kim DW, Mehra R, et al. Ceritinib in 
ALK-Rearranged Non–Small-Cell Lung Cancer. 
New Eng J Med 2014;370:1189–1197. doi:10.1056/
NEJMoa1311107.
Reliable prognostic factors for predicting radiotherapy (RT) 
responses are important to select patients for aggressive RT. 
18F-fluorodeoxyglucose (FDG) positron emission tomography 
(PET)/computed tomography (CT; 18F-FDG PET/CT) has been used 
in diagnosing, restaging at recurrence, determining RT targets and 
effects from RT or chemotherapy in patients with NSCLC. This 
meta-analysis reviewed 13 studies identified from the literature 
(2005–2013) to evaluate the prognostic values of primary tumor 
maximum standardized uptake value (SUV
max
) derived from 18F-
FDG PET/CT in NSCLC patients receiving RT. Overall survival 
Ceritinib (LDK378) is a new ALK inhibitor, which has been 
shown to be more potent than crizotinib, and exhibited marked 
antitumor activity in both crizotinib-sensitive and crizotinib-
resistant tumors in ALK-positive NSCLC preclinically. In this 
phase I study, 59 patients with ALK-positive advanced NSCLC 
received 50–750 mg once daily of ceritinib in the dose-escalation 
phase whereas 71 patients received the maximum tolerated dose 
(750 mg/d) in the expansion phase. The overall response rate in 
patients who received ≥ 400 mg/d of ceritinib was 58%, with a 
median progression-free survival of 7.0 months. Patients receiving 
•	 Transcriptomic 
Architecture of the 
Adjacent Airway Field 
Cancerization in non–
small Cell Lung Cancer 
This is the first comprehensive study in non–small-
cell lung cancer (NSCLC) on the gene expression of 
the adjacent airway field cancerization, a phenomenon 
in which large areas of cells are affected by changes 
leading to cancer. Resected early-stage NSCLC (I-IIIA) 
samples from 20 patients, normal-appearing adjacent 
airways and uninvolved lung tissue were analyzed by 
whole-transcriptome expression profiling. Differentially 
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•	 short-Term Cigarette 
smoke exposure Leads to 
Metabolic Alterations in 
Lung Alveolar Cells
as evidenced by increased palmitate transport 
into the cells and mitochondria. The enhanced 
palmitate consumption for energy production 
in turn disrupted the surfactant biosynthesis 
pathway: phosphatidylcholine levels declined and 
phospholipase A2 activity increased. To conclude, 
this study sheds lights on the mechanism of surfactant 
deficiency in smokers and suggests a potential target 
to tackle the onset of COPD.
Agarwal AR, Yin F, Cadenas E. Short-term cigarette 
smoke exposure leads to metabolic alterations in 
lung alveolar cells. Am J Respir Cell Mol Biol 2014. 
doi:10.1165/rcmb.2013-0523OC.
expressed gene features (n = 1661) were identified 
between NSCLCs and airways versus normal lung 
tissues. A statistically significant difference of a subset 
of these changes (n = 299) was observed between 
airways in lung cancer patients and those in cancer-
free smokers (p < 0.001). Moreover, significant and 
progressive differential expression of 422 genes and 
cancer-associated signaling pathways in airways by 
distance from tumors was found between NSCLCs 
and normal lung tissues. Significantly higher level of 
LAPTM4B, which has been found in other solid tumors, 
were detected in airways closer to tumors (p < 0.05), 
and in cancer cells versus normal bronchial epithelial 
cells (p < 0.001). Overexpression of LAPTM4B can 
induce certain chemotherapy resistance. Further studies 
were planned in larger populations to evaluate field 
cancerization in other lung cancer subtypes and in 
smokers and nonsmokers. The findings on adjacent 
airway field cancerization could shed lights on NSCLC 
carcinogenesis and detection.
Kadara H, Fujimoto J, Yoo S-Y, et al. Transcriptomic 
architecture of the adjacent airway field cancerization 
in non–small cell lung cancer. J Natl Cancer Inst 2014. 
doi:10.1093/jnci/dju004.
Agarwal et al. investigated the effect of cigarette smoke (CS) 
exposure on the metabolism in alveolar type II cells in vivo. Mice 
were exposed to either air or CS produced by a smoking machine 
for 4 or 8 weeks. Alveolar type II cells were collected for 
analysis. The findings showed that acute CS exposure resulted in 
alveolar destruction. The XF Extracellular Flux Analyzer revealed 
the effect of CS exposure on cellular respiration, indicating 
altered glycolysis and increase in palmitate consumption, 
•	 Clove Cigar sales 
Following the us Flavored 
Cigarette Ban
United States from the USDA (2008–2012). The results 
demonstrated a dramatic increase in clove cigar sales by 
greater than 1400% between 2009 and 2012 immediately 
after the ban. A shift from cigarettes to almost exclusively 
cigars in the tobacco imports from Indonesia to the United 
States was also observed in the same period. The authors 
concluded that Kretek International manipulated the 
regulatory loopholes after the ban and replaced the banned 
clove cigarettes with clove cigars, of which consumption 
was therefore increased dramatically recently.
Delnevo CD, Hrywna M. Clove cigar sales after 
the US flavored cigarette ban. Tob Control 2014. 
doi:10.1136/tobaccocontrol-2013–051415.
Delnevo and Hrywna reviewed industry documents and reported the 
changes in marketing and production strategies of Kretek International 
(Djarum cloved cigars parent company) after the ban on flavored 
cigarettes that included clove cigarettes, excluding cigars, by the 
US Family Smoking Prevention and Tobacco Control Act in 2009. 
The analysis covered clove cigar sales trends in the United States 
(2009–2012) after the ban, and tobacco imports from Indonesia to the 
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•	 A Review of smoking 
Policies in Airports Around 
the World 
smoking, whereas 40% were smoke free. Although 71.4% 
of the airport locations allowed more stringent smoke-
free laws at the subnational level versus the national level, 
these laws were implemented in only half of these places. 
Taken together, airports are often being overlooked in 
national or subnational smoke-free policies. Actions are 
needed in lowering secondhand smoke exposure among 
travelers and workers in airports with smoke-free policy 
enforcement, and informing future airport tobacco control 
policy with consistent terminology and definitions.
Stillman FA, Soong A, Kleb C, Grant A, Navas-
Acien A. A review of smoking policies in airports 
around the world. Tob control 2014. doi:10.1136/
tobaccocontrol-2013–051364.
•	 FDA e-cigarettes: Impact 
on Individual and 
Population health. 
This is an open access supplement to the journal, 
Tobacco Control, comprising original articles that 
highlight the current knowledge and research gaps with 
regards to e-cigarettes in product design, chemistry, and 
toxicology of the contents of e-liquid and vapor, human 
risk factors, abuse liability, clinical pharmacology 
and human health effects, and issues on pediatric and 
environment.
Tob Control 2014;23(suppl 2):1–58.
This is a review conducted by Stillman et al. to compare smoking 
policies of 34 major international airports in five world regions with 
the corresponding national and subnational legislation on smoke-free 
indoor places. Anecdotal data on smoking regulations and practices in 
specific airports from an online traveler website were also included in 
the review. Over 50% of the airports had designated smoking areas. 
About 56% of the airport locations had national legislation allowing 
designated smoking areas, whereas 35.3% were smoke free. Sixty 
percent of the airport locations had subnational legislation restricting 
neWs In BRIeF
•	 eLCC 2014: PD-L1 and 
PD-1 expression in 
Molecularly selected non-
small-Cell Lung Cancer 
(nsCLC) Patients 
In gefitinib or erlotinib-treated cohorts, PD-L1-
positive patients, when compared with PD-L1-negative 
patients, were correlated with higher response rate 
(RR: 61.2% versus 34.8%, p = 0.010), longer time to 
progression (TTP, 11.7 versus 5.7 months, p < 0.0001)  
and longer overall survival (OS, 21.9 versus 12.5 
months, p = 0.087). In the subset of patients with 
EGFR mutation receiving EGFR tyrosine kinase 
inhibitors (TKIs), PD-L1 expression was associated 
with longer TTP (13.0 versus 8.5 months, p = 0.011) 
and a trend of better OS (29.5 versus 21.0 months, 
p = 0.752). There was no difference in RR, TTP, 
and OS between PD-1-positive and PD-1-negative 
patients. These results warrant further studies of the 
combination of PD-L1 or PD-1 blockade with EGFR 
TKIs or other targeted therapies to improve outcome of 
patients with EGFR or KRAS mutant NSCLC.
At the Fourth European Lung Cancer Congress (ELCC), 
D’Incecco and colleagues presented the findings of their study 
on the expression of programmed death 1 (PD-1) and its ligand, 
PD-L1, in 125 NSCLC patients harboring mutated EGFR (44.8%), 
mutated KRAS (23.2%), ALK translocation (8%), and wild-type 
EGFR/KRAS/ALK (24%). There was a significant association 
between PD-L1 expression and EGFR mutations (p < 0.0001) 
and between PD-1 expression and KRAS mutations (p = 0.005). 
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•	 eLCC 2014: Programmed 
Cell Death 1 Ligand 1 
(PD-L1) expression and 
Association with survival 
in Mesothelioma
lymphocytic infiltration was observed between PD-L1-
positive and PD-L1-negative patients. PD-L1-positive 
patients were less likely to undergo surgery as a result  
of disease progression (p = 0.001) and had poorer 
survival compared with PD-L1-negative patients  
(6 versus 14 months; p < 0.0001). Its association with 
poor survival remained significant after adjusting for 
age, gender, lymphocytic infiltration, and therapeutic 
surgical intervention (risk ratio 1.73; p = 0.0002). Taken 
together, substantial PD-L1 expression in MPM and 
its correlation with worse survival could be valuable in 
MPM patient management.
Mansfield et al. evaluated the potential of PD-L1 as a therapeutic 
target by analyzing its expression in 224 cases (1986–2003) of 
malignant pleural mesothelioma (MPM) and its association with 
clinical outcome. The findings, presented at the ELCC 2014, 
demonstrated that PD-L1 was expressed in 40% of the study 
samples. No difference in gender, age, decade of diagnosis, or 
•	 eLCC 2014: Clinical 
utility of a Plasma-Based 
MicroRnA signature 
Classifier within 
Computed Tomography 
Lung Cancer screening
randomized Multicentre Italian Lung Detection (MILD) 
trial. Across both low-dose CT (LDCT, n = 652) and 
observation arms (n = 287), MSC for lung cancer 
detection demonstrated 87% sensitivity and 81% 
specificity, and 88% and 80% respectively in the LDCT 
arm. LDCT had sensitivity of 79% and specificity of 
81%. In all subjects, the negative predictive value of 
MSC for detection was 99% and that for death-by-
disease was 99.86%. LDCT false-positive rate dropped 
from 19.4% to 3.7% when combined with MSC. MSC 
risk groups were significantly correlated with survival 
(p < 0.0001). All in all, the results from this large 
validation study demonstrated the predictive, diagnostic, 
and prognostic value of MSC and its potential in 
enhancing LDCT efficacy in lung cancer screening.
Plasma microRNAs (miRNAs) signatures have been reported 
previously to have strong predictive, diagnostic, and prognostic 
values in disease-free smokers from two independent spiral-CT 
screening trials. Pastorino et al. of the same group presented their 
findings at ELCC 2014 on a retrospective study of the diagnostic 
performance of a plasma microRNA signature classifier (MSC) 
in smokers (69 lung cancer and 870 disease free) enrolled in the 
•	 AACR 2014: MK-3475 
(Anti-PD-1 Monoclonal 
Antibody) for non-small 
Cell Lung Cancer (nsCLC): 
Antitumor Activity and 
Association with Tumor 
PD-L1 expression 
MK-3475, whose tumor response were analyzed by 
immune-related response criteria (irRC) and by RECIST 
v1.1. Immunohistochemistry was used to assess tumor 
PD-L1 expression. The entire cohort showed an ORR 
of 24%, median PFS of 9 weeks, and median OS of 51 
weeks. Of the 31 patients with evaluable tumor, tumor 
PD-L1 expression was significantly associated with ORR 
(p < 0.001), PFS (p = 0.004), and OS (p = 0.024). The 
authors concluded that there is a significant association 
between tumor PD-L1 expression and tumor response, 
PFS and OS in NSCLC patients treated with MK-3475. 
Together with the preliminary finding of low tumor 
PD-L1 expression in association with modest antitumor 
activity, this study suggests the role of PD-L1 as a 
biomarker for NSCLC patients receiving MK-3475 
treatment.
At the 105th American Association for Cancer Research (AACR) 
Annual Meeting, Gandhi et al. presented updated data on the 
relationship of tumor PD-L1 expression with overall response rate 
(ORR), progression-free survival (PFS), and overall survival (OS) 
from the treatment with MK-3475, an anti-PD-1 antibody. The phase 
I study included 38 previously treated NSCLC patients receiving 
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•	 AACR 2014: Identification 
of somatic Mutations in 
eGFR/KRAs/ALK-negative 
Lung Adenocarcinoma 
from never smokers
genes that were not reported in lung adenocarcinomas 
previously, such as SETD2 and PBRM1 (chromatin 
remodeling), CHEK2 and CDC27 (cell cycle), CUL3 
and SOD2 (oxidative stress), and CSMD3 and TFG 
(immune response). This indicates the diversity of 
the mutations found in EGFR/KRAS/ALK-negative 
lung adenocarcinoma in never smokers. The highly 
mutated gene was TP53 (11%); most of the mutations 
involved genes in cell cycle/DNA repair (p < 0.001) and 
cAMP-mediated protein kinase A signaling (p < 0.001). 
This result indicated that cell cycle/DNA repair was 
potentially disrupted in lung tumorigenesis and could be 
candidate therapeutic targets.
•	 AACR 2014: Telomere 
Length in White Blood Cell 
DnA and Lung Cancer: A 
Pooled Analysis of Three 
Prospective Cohorts
diagnosis and measurement of telomere lengths using 
monochrome multiplex quantitative PCR in a total of 
matched 847 cases and 847 controls. Consistent with 
findings from the ATBC and SWHS studies, the PLCO 
trial demonstrated that longer telomere length was 
significantly associated with lung cancer risk (adjusted 
odds ratio, OR: 1.00; p-trend = 0.011). The pooled 
analysis had an adjusted OR of 1.00 and p-trend of 
0.000022. Patients with adenocarcinoma were diagnosed 
more than 6 years after blood collection showed a more 
pronounced association. The authors concluded that 
increased telomere length in white blood cell DNA 
could be a biomarker of increased lung cancer risk in 
diverse populations.
This study aimed to analyze the genetic profile of EGFR/KRAS/
ALK-negative lung adenocarcinoma (n = 70) of never-smoker 
patients using whole exome sequencing. Kim et al. presented their 
findings at the AACR annual meeting 2014 in San Diego, CA. 
Among the 27 genes identified, there were genes in the PI3K/mTOR 
signaling and receptor tyrosine kinase signaling in addition to some 
To determine the association of telomere length with risk of lung 
cancer, Seow et al. pooled their analysis of prospective cohorts 
from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer 
Screening Trial in the United States, with the Alpha-Tocopherol, 
Beta-Carotene Cancer Prevention (ATBC) trial in ever smoking 
males in Finland, and the Shanghai Women’s Health Study 
(SWHS) in primarily never smoking women. Analysis of the 
three studies included blood samples collected before lung cancer 
•	 AACR 2014: Differences 
in nicotine Metabolism 
Among Five Racial/ethnic 
Groups with Disparate 
Risks for Lung Cancer: The 
Multiethnic Cohort study
[3-OH]) were measured. Urinary nicotine equivalents 
(NE; sum of total cotinine, total nicotine and 
total 3-OH) were quantified for smoking dose. 
Glucuronidation of each nicotine metabolite and 
CYP2A6 enzymatic activity were also analyzed. 
Significant difference was found in NE, glucuronidation 
of nicotine metabolites, and CYP2A6 activity between 
race/ethnicity (p ≤ 0.002). Highest levels of NE and 
CYP2A6 activity were observed in AA. Also, higher 
NE was significantly associated with higher CYP2A6 
activity for all racial/ethnic groups except NH (p 
interaction < 0.005). The study demonstrated that the 
influence of CYP2A6 activity on smoking dose was 
beyond cigarettes per day and warrants further studies 
on nicotine biomarkers and racial differences in lung 
cancer risk.
Park et al. aimed to dissect the underlying mechanism of 
the different lung cancer risk across racial ethnic groups by 
investigating nicotine metabolism, which in turn affects smoking 
behavior, in 2300 smokers without cancer from five racial/ethnic 
groups: African Americans (AA), Native Hawaiians (NH), Japanese 
Americans (JA), and Latinos (LA). Total and free urinary nicotine 
metabolites (nicotine, cotinine, and trans-3-hydroxycotinine 
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•	 uK Lung Cancer Rates 
Raised by Three Quarters 
in Women While halving 
in Men
A 20% drop in lung cancer incidence was observed in 
overall UK population. The findings call for renewed 
efforts to tackle the disease and changing attitudes 
toward lung cancer. Cancer Research UK emphasized 
key priorities, such as improving awareness of lung 
cancer signs and symptoms, continue to reduce smoking 
incidence through implementation of plain packaging 
for tobacco products, support for smokers to quit 
smoking, and addressing the attitude that lung cancer 
diagnosis is a death sentence.
•	 Trade Agreements, IsDs 
and Plain Packaging
with complaints about tobacco laws. These countries 
include Ukraine, Honduras (British American Tobacco 
has admitted providing direct assistance to these 
two), Indonesia, the Dominican Republic, and Cuba. 
ISDS provisions, reports the paper, are now under 
reconsideration; various countries, including Australia, 
have negotiated or are negotiating free trade agreements 
without ISDS provisions. The intricacies of all of this 
are also highlighted by a paper from the Center for 
Policy Analysis on Trade and Health (http://www.cpath.
org/sitebuildercontent/sitebuilderfiles/CPATH_PITAC.
pdf). Their website (www.cpath.org) includes links to 
information on the Trans Pacific Partnership Agreement 
(TPPA) a major trade agreement subject to “tobacco 
giant subterfuge” (ed.). Much of this is unfamiliar 
territory to the non-industrial relations community, but 
for those of us in the scientific and clinical communities 
buoyed by the successful introduction of plain 
packaging, these complex multilayered attacks call for 
our attention, understanding, and opposition.
The full article from The Saturday Paper is available 
at http://www.thesaturdaypaper.com.au/opinion/
topic/2014/03/08/big-tobaccos-plan-stub-out-plain-
packaging/1394197200#.UyL8NIWeZl
A new Cancer Research UK report revealed an increase of 73% in 
lung cancer incidence in women over the last four decades (23.5 per 
100,000 in 1975 to 40.6 in 2011). In contrary, incidence in men has 
declined by 47% over the same period (111.8 per 100,000 to 59.0). 
The introduction of plain packaging for cigarettes is seen as a major 
advance in tobacco control. Plain packing legislation was introduced 
in Australia in 2012, coming into full effect in December 2012. 
The April issue of The Saturday Paper, an Australian weekly (www.
thesaturdaypaper.com.au) reports on the legal process underway to 
oppose this, taking place between Australia’s trade lawyers and the 
tobacco company Philip Morris, International (PMI). The paper 
reports this as an abuse of international trade agreements. The core 
of the attempt by PMI is based on Investor-State Dispute Settlement 
(ISDS) provisions contained within trade agreements to protect 
companies from poor decisions by governments in countries with 
weak or biased legal systems. These provisions allow corporations 
to take legal actions, such as that taken by PMI against Australia; 
such provisions have been used by other industries, including 
mining and the pharmaceutical industries. It is a complex arena, 
involving other countries brought into conflict with Australia 
•	 Tobacco Farms, smoking 
Rates, the Attorneys-
General, and the 
Pharmacies
often/). Factors that may relate to smoking prevalence 
include the high number of tobacco farms in the state—
Kentucky with 30% smoking prevalence; Mormon 
population—Utah, where 5% of Mormons smoke, below 
the national average and perhaps most amenable to 
intervention, strict smoking bans (workplace, restaurants, 
and bars) present in the 10 states with the lowest 
smoking rates in the United States (Utah, California, 
Minnesota, Massachusetts, New Jersey, Maryland, 
Washington, Rhode Island, Colorado, Arizona).
The decision of the American drugstore CVS to stop 
selling tobacco products by October 2014 has received 
wide acclaim and coverage by many news outlets 
including National Public Radio (http://www.npr.org/
The Washington Post, on March 14, 2014, reported on the prevalence 
of smoking in various states across the United States (http://www.
washingtonpost.com/blogs/govbeat/wp/2014/03/14/the-united-states-
of-smoking-the-state-with-the-most-tobacco-farms-smokes-most-
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blogs/thetwo-way/2014/02/05/271906167/cvs-to-stop-
selling-tobacco-products) and the Wall Street Journal, 
Reuter, and CNN. This decision has now been followed 
by calls from state Attorneys-General to five other major 
retailers to do the same, including Walgreens, Rite Aid, 
Wal-Mart, Safeway, and Kroger. A brief report from 
NPR covers the CVS decision, reporting a possible 
$2 billion loss in annual revenue from the company’s 
7600 pharmacies (second behind Walgreens with 8200 
pharmacies).
